Protocol Ledger

NCT06259526 · Phase II · COMPLETED

A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Interventional Phase II clinical trial protocol NCT06259526 sponsored by Tasly Pharmaceutical Group Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-26 Enrollment: 267 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06259526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)267 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06259526
Protocol FieldVerified Registry Value
NCT IdentifierNCT06259526
Consolidated Lead SponsorTasly Pharmaceutical Group Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment267 participants (ACTUAL)
Registered Start Date2023-12-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06259526
Hospital Research SiteLocationSite Profile
The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI